斯特罗梅利辛促进剂5A/6A多态性与急性心肌梗塞有关
M Terashima1, H Akita, K Kanazawa
1First Department of Internal Medicine, Kobe University School of Medicine, Kobe, and Himeji Cardiovascular Center, Hyogo, Japan.
Circulation
|June 3, 1999
概括
一种常见的遗传变异,即斯特罗梅利辛基因促进体中的5A/6A多态,是急性心肌梗塞 (AMI) 的重要危险因素. 这一发现突出了导致心脏病发作的新途径.
科学领域:
- 心血管遗传学 心血管遗传学
- 分子生物学分子生物学
- 动脉样硬化的发病因子
背景情况:
- 斑块破裂是导致急性心肌梗塞 (AMI) 的关键事件.
- 矩阵金属蛋白酶 (MMPs),包括 stromelysin,涉及到削弱动脉样硬化斑块盖.
- 斯特罗梅利辛基因促进体中常见的5A/6A多态可能会影响基因转录.
研究的目的:
- 调查斯特罗梅利辛基因5A/6A多态性和AMI风险之间的关联.
- 确定这种基因变异是否是AMI的独立风险因素.
主要方法:
- 对330名AMI患者和330名对照人进行了病例控制研究.
- 在 stromelysin 基因促进体中进行了 5A/6A 多态的基因定型.
- 使用统计分析,包括后勤回归来评估相关性.
主要成果:
- 与对照组 (32.7%) 相比,5A/6A+5A/5A基因型在AMI患者 (48.8%) 中明显更为普遍.
- 与5A/6A+5A/5A基因型相关的AMI的几率比为2.25.
- 这种关联在统计学上仍然显著,并且独立于其他心血管风险因素.
结论:
- 斯特罗梅利辛基因促进体中的5A/6A多态性代表了AMI的新型致病遗传风险因素.
- 这种遗传变异可能在急性心肌梗塞的发展和进展中发挥作用.
相关概念视频
Drugs Affecting Neurotransmitter Release or Uptake
Certain drugs can affect how neurotransmitters called catecholamines, are released or taken back up in the adrenergic neuron. They can have different effects on the body's sympathetic transmission. Reserpine, a natural compound found in the Rauwolfia shrub, blocks a transporter called vesicular monoamine transporter (VMAT), which leads to a buildup of catecholamines in the cell and reduces sympathetic transmission. Another drug called guanethidine works in multiple ways, including blocking...
Heart Failure Drugs: Inotropic Agents
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure Drugs: β-Blockers
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Acute Coronary Syndrome I: Introduction
Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...
Cardiopulmonary Resuscitation IV: Pharmacological Management
Pharmacologic intervention is crucial in treating cardiac arrest patients during ACLS or Advanced Cardiovascular Life Support. The ACLS algorithms guide the administration of specific drugs based on the patient's cardiac arrest rhythm, which includes pulseless ventricular tachycardia (VT), ventricular fibrillation (VF), asystole, and pulseless electrical activity (PEA).EpinephrineIndication: Epinephrine is the first-line drug for all cardiac arrest rhythms.Mechanism of Action: Epinephrine...


